Breaking News From ADA 2020
This page was last updated at 7:46 am PT June 16, 2020.
Editor’s Note: This article will be updated regularly with breaking news and announcements during the course of the ADA Scientific Sessions Conference. Check back often! Follow along on twitter at #ADA2020
Tuesday, June 16, 2020
- New rapid-acting insulin Lyumjev from Lilly receives FDA approval for type 1 and type 2 diabetes. More information to come on the specific time to action, prescribing information indicates that it should be taken at meals or up to twenty minutes following meals, and is designed to manage after-meal spikes better than Humalog or similar insulins. It is not yet approved for use in insulin pumps or for children.
Monday, June 15 2020
- Results from the Trends in Glycemic Control among Youth with Diabetes: The SEARCH for Diabetes in Youth Study revealed that despite the increased availability of diabetes technology, new therapies and more aggressive control targets, today’s young adults and youth have worse glycemic control than previous youth and young adult groups from 2002-2007. Data shows these new groups currently aren’t meeting A1C recommendations. Youth and young adults with type 1 diabetes had an average A1c with 8.7 percent, while those with type 2 diabetes had an estimated average A1c of 8.5 percent. “Given the evidence highlighting the benefits of tight glycemic control, this study reinforces the need for interventions that combine the use of diabetes technology with effective behavioral and social approaches to improve A1C levels,” said the study’s lead author Faisal Malik, MD, MSHS, assistant professor of pediatrics at the University of Washington School of Medicine, investigator at the Center for Child Heath, Behavior and Development at Seattle Children’s Research Institute, and a pediatric endocrinologist at Seattle Children’s Hospital.
- Abbott announced that the FDA has approved the FreeStyle Libre 2 System—it is approved for adults and children 4 and up in the United States. The FreeStyle Libre 2 is a 14 day continuous glucose monitor (CGM) system that transmits data every minute and now includes customizable high and low alerts without the need to scan the device. The Abbott announcement says it will be “a third of the cost of other CGMs.”
- One Drop unveiled new AI-powered predictions for blood glucose, A1C, blood pressure and weight up to six months in advance, as well as overnight hypoglycemia predictions For CGM Users. The company plans to roll these features out to users within the year.
Saturday, June 13 2020
- Medtronic presented data on its extended wear infusion set with the ability to be used for up to seven days. Clinical studies on multiple infusion set platforms demonstrated that the Medtronic Extended infusion set is safe and effective for up to seven days, more than twice as long as current Medtronic three-day infusion sets. This new infusion set aims to extend patient wear time by maintaining insulin stability and using new adhesive technology.
- A nationwide study from France showed overall diabetic ketoacidosis (DKA) rates were reduced in the year following FreeStyle Libre system initiation by 52 percent for patients with T1D and 47 percent for patients with type 2 diabetes (T2D). The results were expectedly even more impressive for those who had not been monitoring their blood sugar prior to (60 percent reduction in T1D, 51 percent in T2D).
- Additionally, new late-breaking data demonstrated use of its FreeStyle Libre system is associated with significant reduction in HbA1c levels for people living with type 2 diabetes on either long-acting insulin or non-insulin therapy.
Friday, June 12 2020
- Medtronic presented results from its U.S. pivotal trial of its investigational MiniMed™ 780G Advanced Hybrid Closed Loop (AHCL) system. Results of the 90-day showed improved A1C, Time in Range and higher user satisfaction scores.
- Insulet also presented the results of their pre-pivotal trial of Omnipod 5, powered by Horizon. Omnipod 5 demonstrated improved Time in Range, A1C, and 97 percent of time spent in closed loop. The pivotal trial for the device is currently underway, expecting to ship in the second half of 2021 in the US.
Thursday, June 11 2020
- Mylan and Biocon announced that the FDA has approved Semglee™ (insulin glargine injection), in vials and pre-filled pens for patients with type 1 and type 2 diabetes. Semglee has an identical amino acid sequence to Sanofi’s Lantus and 1the biosimilar drug is approved for the same indications.
- Medtronic announced CE Marking (European Approval) of its MiniMed™ 780G system, a next generation closed loop insulin pump system. The 780G system enables the personalization of blood glucose goals with an adjustable target setting as low as 5.5 mmol/L100 mg/dL, and is expected to begin shipping this Fall in select countries in Europe.
- In a press release previewing Insulet’s ADA 2020, the company formally announced that their next generation closed loop system—previously known as Omnipod Horizon—has been rebranded as Omnipod® 5 Automated Glucose Control System, Powered by Horizon™ (Omnipod 5 for short).
Click here for complete coverage of ADA 2020 from Beyond Type 1.